PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC…
| Price | $4.73 |
|---|---|
| Market cap | $2.15M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 4.401-2671.2 |
| Beta | -0.25 |
Explore ELAB's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.